Article Text

other Versions

PDF
The B cell in systemic lupus erythematosus: a rational target for more effective therapy
  1. D B Driver (catherine.driver{at}cshs.org)
  1. Cedars-Sinai Medical Center, United States
    1. M Ishimori (mariko.ishimori{at}cshs.org)
    1. Cedars-Sinai Medical Center, United States
      1. M H Weisman (weisman{at}cshs.org)
      1. Cedars-Sinai Medical Center, United States

        Abstract

        Current treatment options for systemic lupus erythematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B-cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B-cell function, the advent of new targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.

        • B-cells
        • pathogenesis
        • systemic lupus erythematosus

        Statistics from Altmetric.com

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.